Print

RXi Pharmaceuticals (RXII) Announces Initiation of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109  
12/5/2012 10:46:55 AM

WESTBOROUGH, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (OTC: RXII), today announced that dosing with their anti-scarring drug, RXI-109, for the management of surgical and hypertrophic scars and keloids has been initiated. Nine subjects (3 cohorts of 3) are participating in this dose escalation study during which intradermal injections of RXI-109 will be administered on 3 occasions over 2 weeks. Dose levels range from 2.5 to 7.5 mg per injection, and subjects will receive injections of RXI-109 and vehicle at small incisions on separate areas of their abdomen. Data on safety and tolerance will be collected and evaluated. The incisions will also be evaluated for possible drug effects on the scarring.
//-->